
Frontiers in Pharmacology, Год журнала: 2024, Номер 15
Опубликована: Окт. 17, 2024
There is growing recognition of the potential cannabis to treat various medical conditions and symptoms, such as chronic pain, spasticity, epilepsy. However, one biggest challenges assurance a standardized product that contains consistent amount its main psychoactive substances delta-9-tetrahydrocannabinol (THC) cannabidiol (CBD), which compliant with predetermined specifications for these compounds. This crucial not only ensure quality dosage patients but also effectively translate research findings into clinical practice.
Язык: Английский